Introduction

Advanced head and neck (H&N) tumors have poor prognoses. In advanced stages, patients can die as a result of systemic metastases but most of the patients will die as a direct effect of the main tumor, or from regional node involvement. In this situation, regional disease is not, generally, amenable to surgical resection and radical treatment is usually radiotherapy, with or without chemotherapy.

A way to improve the efficacy of the radiotherapy is to use altered (non-standard) fractionations that allow a higher final dose of radiation to be administered, or the same final dose but administered over a shorter time. Hyperfractionated radiotherapy (two small fractions of radiotherapy every day) and the technique of concurrent boost (one standard fraction plus another small fraction in a reduced field, every day) are the

Original Article

Adjuvant Ozonetherapy in Advanced Head and Neck Tumors: A Comparative Study

Bernardino Clavo1,7, Ana Ruiz1,7, Marta Lloret1,7, Laura López1,7, Gerardo Suárez1,7, David Macías2,7, Victor Rodríguez6, Maria A. Hernández1,7, Roberto Martín-Oliva2, Santiago Quintero3, José M. Cuyás4 and Francisco Robaina5,7

1Department of Radiation Oncology-Research Unit, 2Department of Medical Physics, 3Department of Oral and Maxillofacial Surgery, 4Otolaryngology and 5Department of Neurosurgery and Chronic Pain Unit of the Dr Negrín Hospital, Las Palmas, Canary Islands, 6La Paterna Medical Center, Las Palmas, Canary Islands and 7Canary Islands Institute for Cancer Research (ICIC), Las Palmas, Canary Islands, Spain

Advanced head and neck (H&N) tumors have a poor prognosis, and this is worsened by the occurrence of hypoxia and ischemia in the tumors. Ozonetherapy has proved useful in the treatment of ischemic syndromes, and several studies have described a potential increase of oxygenation in tissues and tumors. The aim of this prospective study was to evaluate the clinical effect of ozonetherapy in patients with advanced H&N cancer in the course of their scheduled radiotherapy. Over a period of 3 years, 19 patients with advanced H&N tumors who were undergoing treatment in our department with non-standard fractionated radiotherapy plus oral tegafur. A group of 12 patients was additionally treated with intravenous chemotherapy before and/or during radiotherapy. In the other group of seven patients, systemic ozonetherapy was administered twice weekly during radiotherapy. The ozonetherapy group was older (64 versus 54 years old, \( P = 0.006 \)), with a higher percentage of lymph node involvement (71% versus 8%, \( P = 0.019 \)) and with a trend to more unfavorable tumor stage (57% versus 8% IVb + IVc stages, \( P = 0.073 \)). However, there was no significant difference in overall survival between the chemotherapy (median 6 months) and ozonetherapy (8 months) groups. Although these results have to be viewed with caution because of the limited number of patients, they suggest that ozonetherapy could have had some positive effect during the treatment of our patients with advanced H&N tumors. The adjuvant administration of ozonetherapy during the chemo–radiotherapy for these tumors merits further research.

Keywords: altered fractionation – alternative medicine – cancer – chemotherapy – radiotherapy – tegafur

For reprints and all correspondence: Bernardino Clavo, Department of Radiation Oncology & Research Unit, Hospital Dr Negrín, C/ Barcón la Ballena s/n, 35020 Las Palmas, Canary Islands, Spain. Tel: +34-928-450284; Fax: +34-928-449127; E-mail: bernardinoclavo@terra.es

The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated.

© 2004, the authors

Evidence-based Complementary and Alternative Medicine, Vol. 1, Issue 3 © Oxford University Press 2004; all rights reserved
most usual altered fractionations that have produced improved clinical outcomes (1).

Another way to improve the efficiency of the radiotherapy in H&N tumors is to decrease the ischemia and hypoxia associated with the tumors. Tumor hypoxia can increase radioresistance by up to 2.5–3 times (2). Additionally, tumor hypoxia predisposes cancer cells to a physiologic selection that results in tumor cells that are more aggressive, have decreased apoptotic potential and also have additional resistance to radiotherapy and chemotherapy (3). In H&N cancer, tumor hypoxia has been shown to be predictive of the response to radiotherapy (4–6) and our experience to date is in concordance with these data (7). As has been demonstrated by Overgaard and Horsman’s meta-analysis (8), improving tumor oxygenation can lead to better local control and increased overall survival rates following radiotherapy.

Ozonetherapy is a technique that has been used in the treatment of ischemic syndromes (9–11). In previous studies we have described a relationship between oxygenation in H&N cancer and in anterior tibialis muscles (12), as well as ozonetherapy-induced improvement in the oxygenation of the ‘most-hypoxic’ anterior tibialis muscles (13), together with improvements in the most hypoxic tumors (14).

The aim of the present prospective study was to evaluate the clinical effect, if any, of ozonetherapy administered to patients with advanced H&N cancer who were undergoing scheduled treatment with altered fractionation radiotherapy and chemotherapy.

### Subjects and Methods

#### Patients

Nineteen patients were recruited into the study. All were male with H&N tumors and were being treated in our department with altered fractionated radiotherapy over a period of 3 years. The tumors were histologically confirmed and were not suitable for surgical resection. The malignancies were advanced H&N tumors, classified as stage IV on the TNM classification (15): tumor size T4 and/or lymph node N2 or N3 (diameter ≥3 cm or multiples). The patients’ performance status was required to be >70% on the Karnofsky scale. The experimental nature of the study was fully explained to the patients and written consent was obtained prior to their recruitment. The study had the full approval of the Institutional Ethical Committee.

The altered radiotherapy consisted of hyperfractionated radiotherapy (120 cGy/fraction, two fractions/day) or hypofractionated radiotherapy (dose/fraction higher than the standard 200 cGy/fraction). Hyperfractionated radiotherapy provides the option of administering a total dose that is 15% higher than standard radiotherapy while hypofractionated radiotherapy offers a quicker and more comfortable schedule of radiotherapy, but with a lower total dose. The hypofractionated schedule is applied, usually, in older patients or those with very poor performance status, or when palliative treatment is the only option. Radiotherapy was from a Cobalt60 source. Daily chemotherapy with tegafur (oral pro-drug of 5-fluorouracil, 800 mg/day) as radiosensitizer was administered to all patients (except two; see ozonetherapy group, below) during the period of radiotherapy.

For the purposes of the present study, there were two treatment groups. In addition to the scheduled radiotherapy, one group had the ozonetherapy and the other had the scheduled chemotherapy. Table 1 summarizes the relevant clinical characteristics of the patients.

#### Chemotherapy Group

There were 12 patients in this group, with an age range between 48 and 61 years. They had been referred to our hospital by the Medical Oncology Department from other hospitals without radiotherapy facilities. Intravenous chemotherapy was administered as neoadjuvant (before radiotherapy) in 11 patients and concurrent (during radiotherapy) in two patients, one of whom received neoadjuvant chemotherapy as well. Neoadjuvant chemotherapy consisted of combinations of intravenous taxotere, platinum and 5-fluorouracil over four cycles (range 3–5 cycles). Concurrent chemotherapy was taxotere administered weekly over the 8 weeks of radiotherapy. All 12 patients received tegafur daily (800 mg/day, orally) as radiosensitizer over the period of the radiotherapy. All the patients were treated with hyperfractionated radiotherapy, with a mean final dose of 78.6 Gy (range 74.4–82.8 Gy)

#### Ozonetherapy Group

There were seven patients in this group with an age range between 52 and 74 years. These patients represent the H&N cancer patients from among those with a variety of other cancers receiving ozonetherapy in our Department. Ozonetherapy was administered twice weekly over the course of the radiotherapy. Of the seven patients, four were treated with the planned hyperfractionated radiotherapy (two fractions/day) and, due to the advanced stage of the disease and patient preference, the other three patients were treated with hypofractionated radiotherapy (one fraction/day; a higher-than-standard-dose/fraction and a lower total dose). Overall, the seven patients in this group received a mean final dose of 75.3 Gy (range 65–81.6 Gy). Of these seven patients, two did not complete the oral tegafur treatment over the period of the radiotherapy because of limited tolerance.

#### Ozonetherapy Technique (OT)

Ozonetherapy was administered twice a week over the period of the radiotherapy. Using clinical-grade O2, the O2/O3 gas mixture was prepared with an OZON 2000 device (Zotzmann + Stahl GmbH, Pläderhausen, Germany) and sterilized by passage through a sterile 0.20 μm filter. Systemic OT was by autologous autohemotransfusion or by rectal insufflation. The autohemotransfusion procedure involved the
extraction of 200 ml venous blood into heparin (25 IU/ml) and CaCl₂ (5mM). In a sterile single-use 300 ml container, the blood was mixed with 200 ml of the O₃/O₂ gas mixture at a concentration of 60 g/ml and then slowly re-introduced into the patient. The blood was extra-corporeal for 15–30 min and there were no adverse reactions except hematoma formation in the area of venous injection. Rectal insuflation was employed when the performance status was low, or at the preference of patient. This procedure consisted in rectal insuflation of 300 ml of O₃/O₂ gas mixture at a concentration of 60 g/ml. The main side effects were transient meteorism and constipation in some patients. In three patients, the intravenous route alone was used, in one patient the rectal insufflation route alone was used and in the other three patients we began the ozonetherapy using autohemotransfusion but then changed to rectal insufflation. Among the seven patients, there were 49 (mean of seven per patient) autohemotransfusion procedures, and 41 (mean of six per patient) rectal insufflations.

Statistical Analyses

The SPSS software package (version 11.0 for Windows) was used for all analyses. Two-sided tests were applied for significance. Data are expressed as means with their 95% confidence intervals (95% CI). Age between groups was compared by the two-sided non-paired Student’s t-test. Nominal group data were compared by chi-square test. Overall survival was evaluated by actuarial analysis using the log-rank test of Kaplan–Meier estimates. P-values <0.05 were considered statistically significant.

Results

The patients in the ozonetherapy group were significantly older than the chemotherapy group: 64 years (range 56–72) and 54 years (range 51–57), respectively (P = 0.006).

The ozonetherapy group had more advanced lymph node involvement. All patients had multiple nodes and/or nodes ≥6 cm, while in the chemotherapy group only 50% of the patients had this advanced node involvement (P = 0.080). In the ozonetherapy group, 71% of patients had large nodes ≥5 cm, while in the chemotherapy group only one patient (8%) had a node ≥5 cm (P = 0.019).

Additionally, there was a trend towards the most unfavorable stages IVb (nodes ≥6 cm) or IVc (systemic metastases) in the ozonetherapy group than in the chemotherapy group (57% versus 8%; P = 0.073).

The percentages of clinically complete response in the irradiated areas were 29% versus 50% in the ozonetherapy and chemotherapy groups, respectively. These differences were not statistically significant.

Median overall survival in the ozonetherapy group was 8 months (median 3–13 months) while the median overall survival in the chemotherapy group was 6 months (median 4–8 months). These differences were not statistically significant (Fig. 1).

Table 1. Clinical characteristics of the patients in the study

<table>
<thead>
<tr>
<th>Treatment group*</th>
<th>Age</th>
<th>Location</th>
<th>Stage1</th>
<th>T*</th>
<th>N*</th>
<th>M*</th>
<th>Node size ≥5 cm*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemo</td>
<td>48</td>
<td>Oropharynx</td>
<td>IVa</td>
<td>4</td>
<td>2a</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Chemo</td>
<td>49</td>
<td>Oropharynx</td>
<td>IVa</td>
<td>4</td>
<td>2a</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Chemo</td>
<td>52</td>
<td>Oropharynx</td>
<td>IVa</td>
<td>4</td>
<td>2c</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Chemo</td>
<td>61</td>
<td>Hypopharynx</td>
<td>IVa</td>
<td>4</td>
<td>0</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Chemo</td>
<td>61</td>
<td>Hypopharynx</td>
<td>IVa</td>
<td>3</td>
<td>2c</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Chemo</td>
<td>53</td>
<td>Hypopharynx</td>
<td>IVa</td>
<td>3</td>
<td>2a</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Chemo</td>
<td>52</td>
<td>Oropharynx</td>
<td>IVa</td>
<td>4</td>
<td>2c</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Chemo</td>
<td>48</td>
<td>Oropharynx</td>
<td>IVa</td>
<td>4</td>
<td>2b</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Chemo</td>
<td>58</td>
<td>Oropharynx</td>
<td>IVa</td>
<td>4</td>
<td>0</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Chemo</td>
<td>61</td>
<td>Oropharynx</td>
<td>IVa</td>
<td>4</td>
<td>1</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Chemo</td>
<td>57</td>
<td>Oropharynx</td>
<td>IVa</td>
<td>4</td>
<td>2c</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Chemo</td>
<td>51</td>
<td>Oropharynx</td>
<td>IVb</td>
<td>2</td>
<td>3</td>
<td>–</td>
<td>6 × 4</td>
</tr>
<tr>
<td>Ozone</td>
<td>52</td>
<td>Nasopharynx</td>
<td>IVa</td>
<td>4</td>
<td>2c</td>
<td>–</td>
<td>5 × 5</td>
</tr>
<tr>
<td>Ozone</td>
<td>68</td>
<td>Hypopharynx</td>
<td>IVc</td>
<td>3</td>
<td>2b</td>
<td>Yes</td>
<td>–</td>
</tr>
<tr>
<td>Ozone</td>
<td>53</td>
<td>Hypopharynx</td>
<td>IVc</td>
<td>4</td>
<td>3</td>
<td>Yes</td>
<td>12 × 10</td>
</tr>
<tr>
<td>Ozone</td>
<td>74</td>
<td>Oropharynx</td>
<td>IVa</td>
<td>4</td>
<td>2c</td>
<td>–</td>
<td>5 × 3.5</td>
</tr>
<tr>
<td>Ozone</td>
<td>63</td>
<td>Supraglottis</td>
<td>IVb</td>
<td>2</td>
<td>3</td>
<td>–</td>
<td>8.5 × 5.5</td>
</tr>
<tr>
<td>Ozone</td>
<td>67</td>
<td>Oral cavity</td>
<td>IVb</td>
<td>4</td>
<td>3</td>
<td>–</td>
<td>8.5 × 5.5</td>
</tr>
<tr>
<td>Ozone</td>
<td>70</td>
<td>Oropharynx</td>
<td>IVa</td>
<td>2</td>
<td>2c</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

*Abbreviations: Chemo, chemotherapy group; Ozone, ozonetherapy group; T, tumor; N, lymph node; M, systemic metastases. †Tumor stage according to AJCC Cancer Staging Manual, 5th Edn (15): stage IVc, systemic metastases; stage IVb, lymph node ≥6 cm; stage IVa, T4 without features from IVb or IVc. * Node largest diameters clinically measured when lymph node size ≥5 cm.
However, tumor vessels have structural and functional abnormalities with decreased or near-absent auto-regulatory mechanisms (26) and, as such, the effects of ozonetherapy on tumor vasculature need to be evaluated in specifically designed in vivo and in vitro studies.

Our ozonetherapy patient group had a poorer prognosis. The patients were older, with larger tumor nodes, at more advanced stages of the disease and with a less-optimized radiotherapy schedule, i.e. lower mean final doses, and three of seven patients were treated with hypofractionated instead of hyper-fractionated radiotherapy. Despite this, the patients in this group were not disadvantaged, as evidenced by the observation that overall survival was not lower than the chemotherapy group even though the latter received a more aggressive chemotherapy and a higher final dose of radiotherapy. These results suggest that ozonetherapy, when applied during radiotherapy, could have had some beneficial effect in these patients with advanced H&N tumors. Further studies are under way in our Department to extend the numbers and types of cancer patients receiving ozonetherapy with a view to making more detailed comparisons of the benefits of ozonetherapy as adjuvant to chemotherapy and radiotherapy together with other adjuvant treatment such as carbogen breathing.

It is of note that an isolated report in the early 1970s had indeed postulated the potential improvement in the effects of radiotherapy by ozonetherapy in advanced gynecological tumors (27). We tend to favor the explanation of the potential positive effect during chemo–radiotherapy as being due to the effects on ischemia–hypoxia, as described above, as well as an increase in sensitivity of tumor cells to chemotherapy with 5-fluorouracil (28). Other potential contributions to the mechanism-of-action that have been described include increase in cytokine production (29,30) among others (31).

In conclusion, tumor hypoxia and ischemia are known to limit treatment efficacy and, hence, the alleviation of such a predisposition to poorer treatment outcome is seen as beneficial. Ozonetherapy can produce an improvement in blood flow and oxygenation in some tissues and although our findings need to be viewed with caution because of the limited number of patients enrolled, ozonetherapy appears to have had some positive effect during the treatment of patients with advanced H&N tumors. The potential usefulness of ozonetherapy as an adjuvant in chemo–radiotherapy for these tumors warrants further investigation.

Acknowledgements

Editorial assistance was provided by Dr Peter R. Turner of t-SciMed (Reus, Spain). This work was partially supported by a grant (FUNCIS 98-31) from the Health and Research Foundation of the Autonomous Government of the Canary Islands (Spain).

References

31. Bocci V. Ozone therapy as a possible biological response modifier in cancer. Forsch Komplementarmed (Research Complementary Medicine, German/English) 1998;5:54–60.

Received March 13, 2004; Accepted August 20, 2004